61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode

Clozapine-induced Hypersalivation

Metoclopramide

placebo

Be'er Sheva Mental Health Center,

Metoclopramide as Treatment of Clozapine-induced Hypersalivation

Vladimir Lerner

Prof. Vladimir Lerner

Beersheva Mental Health Center

Tirat Carmel Mental Health Center

Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.

Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.

Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
Silodosin: 8mg tablet, 1 tab PO daily for 2 weeks

Silodosin

Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
Tamsulosin: 0.4 mg Tab, 1 tab PO daily for 2 weeks

Tamsulosin

Total

Sex: Female, Male

Region of Enrollment

The primary outcome measure will be the time it takes for the stone to pass. Stone passage will be defined as the subject self-reporting passage of a stone that is consistent with their imaging, or resolution of their pain to suggest unseen passage of their stone. This outcome will be measured from the initial emergency department visit, and gathered at the one-week follow-up call as well as the two-week follow-up visit.

Time to Stone Passage

The subject will be given a standardized pain medication prescription at their initial visit, and will be asked to keep track of how much pain medication they used each day, as well as to bring their pill bottle with them to the two-week follow-up appointment for a pill count. This information will be collected at the two-week follow-up appointment.

Use of Pain Medication

Subjects will be given instructions at the initial visit to return to the emergency department immediately for signs and symptoms of infection or MET failure (fever, worsening pain, vomiting, lethargy, unsteadiness, syncope or inability to tolerate oral pain medications). These subjects will be considered to have failed outpatient treatment and will be removed from the study.
Subjects who do not experience these issues but who still report having symptoms at the two-week follow-up visit will also be considered to have failed outpatient treatment.

Outpatient Treatment Failure

Both tamsulosin and silodosin carry the possibility of causing orthostatic hypotension, which can manifest as unsteadiness, syncope, headache, and/or dizziness, especially when changing position from sitting/laying to standing. Subjects will be asked to assess themselves for these symptoms continuously from the initial visit, with serious reactions resulting in cessation of study medication. For reactions which are not serious, the information will be collected at the one-week follow-up call as well as the two-week follow-up visit.

calculi/повръщане

Metoclopramide as Treatment of Clozapine-induced Hypersalivation

Silodosin Versus Tamsulosin for Treatment of Ureteral Stones

Най-пълната база данни за лечебни билки, подкрепена от науката